+34 679 490 537info@nanbiosis.com

Posts Taged eatris

NANBIOSIS in CIBER-BBN ANNUAL CONFERENCE 2017

CIBER-BBN will celebrate its 11th Annual Conference on November 13 and 14 in Santander. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place.

As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation.

As a novelty, it will be presented at the conference, the new internal structure, generated by NANBIOSIS for the development of “turnkey” projects in which, taking advantage of the complementarity and experience of its Units, NANBIOSIS offers complete service packages, with added value, adapted to the client’s needs, for applications such as nanotherapeutic agents, regenerative medicine, medical and diagnostic devices, among others. Some of the packages that are already designed or in more advanced stages will be explained, among which stands out the service of characterization and cascade assessment of nanomaterials that includes the characterization of the physicochemical attributes, their biological properties in vitro (immunology, toxicology and efficacy), and its in vivo compatibility (immunology, toxicology and efficacy), using appropriate animal models, with the possibility of being subject to regulatory conditions of Good Laboratory Practices. Some success stories of these “turnkey” projects developed in NANBIOSIS will be shown.

On this occasion, in addition, it is planned a presentation of EATRIS , the European Infrastructure for the Translation of Medicine, with which NANBIOSIS has initiated a line of collaboration.

Since its launch in July 2015, NANBIOSIS has received more than 550 access requests through its website, with an average participation of some 80 competitive projects per year and with an annual income for its services of between 2 and 3 million euros. Among its users, there are more than 100 companies.

Read More

NANBIOSIS at the EATRIS Conference Translational Medicine 2017

NANBIOSIS  has actively participated in the third bi-annual conference organised by EATRIS, (the European infrastructure for translational medicine) in Prague on 24-26 of September Translational Medicine 2017: Enhancing predictivity in medicines development . The event gathered a wide range of stakeholders (industry, academia, policymakers) and focussed on bringing together the latest approaches to increase chances of success in drug development, from novel in vitro systems to new biomarkers or clinical trial methodology for patient selection and stratification.

Jesús Izco, Coordinator of NANBIOSIS, presented NANBIOSIS initiatives of joint collaboration, which were well received and will be coordinated and developed during the next months.

Read More

NANBIOSIS at the CIBER-BBN X Annual Conference and 1st meeting of the NANBIOSIS SAB

The X Annual Conference of CIBER-BBN, held in Sevilla last 28 and 29 of November, dedicated a Session to NANBIOSIS on Monday afternoon, to which attended national and international representatives of industry and academia users of NANBIOSIS, representatives of EATRIS and members of the Scientific and Technical Advisory Committee of NANBIOSIS, as well as the CIBER-BBN and the CCMIJU researchers.

Jaume Veciana, Scientific of NANBIOSIS and Ángela Fernández Curto, Assistant Deputy Director General for Planning of Scientific and Technological Infrastructures of Spanish Goverment presented the Unique Technical Scientific Infrastructure (ICTS) of CIBER-BBN and JUMISC for the production and characterization of biomaterials, nanomaterials and devices until their preclinical validation. Among the biomedical applications that frame the activity of NANBIOSIS are diagnostic, regenerative medicine and drug administration, as well as its next Cascade Characterization Service for the preclinical evaluation of nanomedicines.

The project “PRONANBIOSIS” funded by the Spanish Ministry of Economy and Competitiveness with a “Network of Excellence” to consolidate the unified management model of NANBIOSIS, to boost its internationalization and strategic positioning as well as to promote a complete nanomaterials characterization cascade service, was also presented and some of the” success stories “of the ICTS where explained.

Since its launch in July 2015, NANBIOSIS has received more than 250 access requests, with an average participation of about 50 competitive projects per year and annual revenues for its services of between 1 and 2 million euros. Among its users, there are more than 100 companies, especially pharmaceutical laboratories, and more than 300 research groups. In addition, its 27 units are involved in several national and European projects, such as BERENICE (nanoformulation of the active to combat Chagas disease), DRIVE (development of a device with pancreatic cells for diabetes treatment) and several public- Former INNPACTO (PHYTEC -Development of bioactive coated medical products for bone regeneration- and VITILIGO -Development of a new advanced therapy drug for the treatment of Vitiligo-), several projects Challenges Collaboration, or the Network of Excellence Pronanbiosis for the promotion and Consolidation of the ICTS, among others.

At the Conference, the NANBIOSIS Scientific Advisory Committee convened to discuss the key actions of its next Strategic Plan, such as the new Cascade Characterization Service for the preclinical evaluation of nanomedicines.

NANBIOSIS at the CIBER-BBN X Annual Conference and 1st meeting of the NANBIOSIS SAB
Read More
Nanbiosis